高级检索
当前位置: 首页 > 详情页

Research Progress of MicroRNA in Chemotherapy Resistance of Osteosarcoma.

文献详情

资源类型:
WOS体系:
Pubmed体系:

收录情况: ◇ SCIE

机构: [1]Department of Orthopaedics, 586778Gansu Provincial Hospital of Traditional Chinese Medicine, Lanzhou, Gansu, China. [2]The Second Clinical Medical College, 12426Lanzhou University, Lanzhou, Gansu, China. [3]Department of Spine Surgery, The Third Affiliated Hospital of Sun Yat-Sen University, Guangzhou, Guangdong, China. [4]The First Clinical Medical College, 12426Lanzhou University, Lanzhou, Gansu, China. [5]Department of Gastroenterology, Gansu Provincial People's Hospital, Lanzhou, Gansu, China.
出处:
ISSN:

关键词: microRNA chemotherapeutic drugs osteosarcoma drug resistance malignant prognostic marker

摘要:
Osteosarcoma (OS) is a malignant tumor prevalent in adolescents; however, a clinically effective treatment for this malignancy is lacking. The lack of effective treatment methods and factors, such as recurrence and drug resistance, further dampen the prospect of clinically treating OS. In recent years, small molecule microRNAs (miRNAs) with a length of approximately 20-24 nucleotides have gradually attracted the attention of the medical community. Studies have found that miRNAs can regulate the cell cycle, apoptosis, cell proliferation, and cell proliferation. The metabolic response of cancer cells, invasion and metastasis of cancer cells, and angiogenesis play an important role in the process of tumorigenesis. miRNAs regulate gene expression by regulating mRNA expression after transcription. A large amount of data from many studies indicate that they have diagnostic and prognostic biomarker effects in OS and are involved in regulating the metabolism of cancer cells and resistance or sensitivity to chemotherapy drugs. Chemotherapy resistance is one of the most critical problems in clinically treating OS. A large number of basic studies and systematic summaries are required to provide a theoretical basis for elucidating the mechanism and drug development of chemotherapeutic agents. Therefore, this article discusses the role of miRNAs in OS resistance. Herein, the related research progress of the studies is reviewed to provide more useful information for the development of effective therapy.

基金:
语种:
WOS:
PubmedID:
中科院(CAS)分区:
出版当年[2020]版:
大类 | 4 区 医学
小类 | 4 区 肿瘤学
最新[2025]版:
大类 | 4 区 医学
小类 | 4 区 肿瘤学
JCR分区:
出版当年[2019]版:
Q4 ONCOLOGY
最新[2023]版:
Q3 ONCOLOGY

影响因子: 最新[2023版] 最新五年平均 出版当年[2019版] 出版当年五年平均 出版前一年[2018版] 出版后一年[2020版]

第一作者:
第一作者机构: [1]Department of Orthopaedics, 586778Gansu Provincial Hospital of Traditional Chinese Medicine, Lanzhou, Gansu, China.
共同第一作者:
通讯作者:
通讯机构: [5]Department of Gastroenterology, Gansu Provincial People's Hospital, Lanzhou, Gansu, China. [*1]Department of Gastroenterology, Gansu Provincial People’s Hospital, Lanzhou, Gansu 730000, China.
推荐引用方式(GB/T 7714):
APA:
MLA:

资源点击量:2020 今日访问量:0 总访问量:646 更新日期:2024-07-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 广东省中医院 技术支持:重庆聚合科技有限公司 地址:广州市越秀区大德路111号